Anrukinzumab - CAS 910649-32-0

Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13) . Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.

IL Receptor, Interleukin

Immunology/Inflammation

910617

0.983

-20°C

Ice Packs

Inhibitory Antibodies